Skip to main content
graph.swiss
Galderma Group AG

Galderma Group AG

172.50 CHF+2.60 (+1.53%)
XSWX:GALDMarket Closed
ListedCHF40.5BHealthcareDrug Manufacturers - Specialty & Generic7,676 employees

Company Profile

Legal NameGalderma Group AG
CEODr. Flemming Ornskov M.B.A., M.D., M.P.H.
HeadquartersZählerweg 10
Phone41 58 455 85 92
Employees (FTE)7,676
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Business Description

Galderma Group AG is a Swiss healthcare company specializing exclusively in dermatology, headquartered in Zug and founded in 1981. The company focuses on skin health through three integrated business segments: injectable aesthetics, dermatological skincare, and therapeutic dermatology. In injectable aesthetics, Galderma Group AG offers physician-administered neuromodulators and dermal fillers under brands such as Dysport, Restylane, Sculptra, Azzalure and Alluzience, serving aesthetic clinics and medical professionals. Its dermatological skincare portfolio centers on consumer-facing brands like Cetaphil and ALASTIN, providing cleansers, moisturizers and targeted skincare solutions for sensitive and problem-prone skin. In therapeutic dermatology, the company markets prescription and non-prescription treatments for conditions including acne, rosacea and other inflammatory skin disorders, with brands such as Epiduo, Differin, Aklief, Oracea, Benzac and Loceryl. Galderma Group AG operates globally in around 90 countries, partnering closely with dermatologists and healthcare professionals to deliver science-based, premium products and services across the full spectrum of the dermatology market.

Profitability & Growth

Profitability

Profit Margin+11.70%
Operating Margin+17.80%
Return on Equity (TTM)+7.69%
Return on Assets (TTM)+4.25%

Recent Year-End

Revenue4.24B
Revenue / Share22.23
Gross Profit2.92B
EBITDA1.19B
Diluted EPS2.09
Earnings Growth YoY+127.70%
Revenue Growth YoY+24.80%

Balance Sheet Snapshot

Total Cash (MRQ)

631.3M

Total Debt (MRQ)

2.23B

Current Ratio (MRQ)

1.19

Book Value / Share

28.12

Stock Statistics

Shares Outstanding234.6M
Float Shares132.6M
Avg Volume (10d)341.6K
Avg Volume (90d)493.4K
% Held by Insiders+21.02%
% Held by Institutions+46.10%

Valuation

Market Cap40.46B
Enterprise Value33.64B
Trailing P/E79.71
Forward P/E31.56
PEG Ratio31.56
Price / Sales (TTM)7.46
Price / Book (MRQ)5.92
EV / Revenue7.93
EV / EBITDA36.65

Price Summary

52-Week Low122.70
52-Week High188.25
50-Day MA168.62
200-Day MA156.49
Beta-0.08

Dividends

Forward Div Rate1.40
Forward Div Yield+0.81%
Trailing Div Rate0.35
Payout Ratio+7.06%
Dividend Date2025-04-29
Ex-Dividend Date2026-04-24